Fruquintinib, a novel oral therapy targeting the VEGF pathway for metastatic colorectal cancer, has been largely studied in patients with normal kidney function, leaving its effects on those with ESRD poorly understood. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.